Infanrix-Ipv+hib (Haemophilus Type B Conjugate Vaccine (Tetanus Toxoid Conjugate), Poliovirus (Inactivated) Type 3 (Sa)

The vaccine contains toxoid and antigen components that are recognized by the immune system. After intramuscular injection, antigen‑presenting cells process the toxoids, pertussis proteins, inactivated poliovirus, and Hib polysaccharide‑tetanus toxoid conjugate, prompting B‑cell and T‑cell activation and the production of protective antibodies and memory cells.

The dosing schedule for Infanrix IPV+Hib is determined by the prescribing healthcare professional based on national immunization guidelines. The vaccine is typically administered as a series of intramuscular injections in the thigh or deltoid muscle at specific ages, but exact timing and number of doses should be set by the prescriber.

Safety data for Infanrix IPV+Hib in pregnant women are limited, and the vaccine is generally not recommended during pregnancy unless the potential benefit outweighs any risk. Limited information is available for breastfeeding; however, inactivated vaccines are not expected to pose a risk to the infant. Consultation with a healthcare provider is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any required import documentation.

Infanrix IPV+Hib combines diphtheria, tetanus, acellular pertussis, inactivated poliovirus type 3 and Hib conjugate in a single injection, reducing the number of separate shots. Alternatives such as Pentacel or Pediacel provide similar protection but may differ in poliovirus serotype coverage or Hib conjugate formulation. Choice depends on national schedules, availability and clinician preference.

The vaccine must be stored refrigerated at 2 °C to 8 °C. It should be kept in the original packaging, protected from light, and must not be frozen or shaken. Before use, the lyophilized powder is reconstituted with the supplied diluent and used promptly according to the product label.

Infanrix IPV+Hib is given by intramuscular injection, usually into the anterolateral thigh for infants or the deltoid muscle for older children. The reconstituted suspension is drawn into a sterile syringe and administered by a qualified healthcare professional following aseptic technique.

Serious adverse events are rare but can include severe allergic reactions (anaphylaxis), febrile seizures, persistent high fever, encephalopathy, and Guillain‑Barré syndrome. Immediate medical attention is required if signs of anaphylaxis (e.g., difficulty breathing, swelling of the face) or prolonged high fever occur after vaccination.

Infanrix IPV+Hib should not be given to individuals with a known severe allergy to any vaccine component or to a previous dose of the vaccine. It is also contraindicated in persons who have experienced a severe reaction to a prior dose of any diphtheria, tetanus, pertussis, poliovirus or Hib vaccine.